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Abstract
Background: We evaluated the effectiveness of the Ortho All-Flex Diaphragm, lubricant gel (ReplensH) and condoms
compared to condoms alone on the incidence of chlamydial and gonococcal infections in an open-label randomized
controlled trial among women at risk of HIV/STI infections.
Methods: We randomized 5045 sexually-active women at three sites in Southern Africa. Participants who tested positive for
curable STIs were treated prior to enrollment as per local guidelines. Women were followed quarterly and tested for
Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (GC) infection by nucleic-acid amplification testing (Roche AmplicorH)
using first-catch urine specimens. STIs detected at follow-up visits were treated. We compared the incidence of first
infection after randomization between study arms in both intent-to-treat (ITT) and per-protocol populations.
Findings: Baseline demographic, behavioral and clinical characteristics were balanced across study arms. Nearly 80% of
participants were under 35 years of age. Median follow-up time was 21 months and the retention rate was over 93%. There
were 471 first chlamydia infections, 247 in the intervention arm and 224 in the control arm with an overall incidence of 6.2/
100 woman-years (wy) (relative hazard (RH) 1.11, 95% Confidence Interval (CI): 0.93–1.33; p=0.25) and 192 first gonococcal
infections, 95 in the intervention arm and 97 in the control arm with an overall incidence of 2.4/100wy (RH 0.98, 95%CI:
0.74–1.30; p=0.90). Per protocol results indicated that when diaphragm adherence was defined as ‘‘always use’’ since the
last visit, there was a significant reduction in the incidence of GC infection among women randomized to the intervention
arm (RH 0.61, 95%CI: 0.41–0.91, P=0.02).
Interpretation: There was no difference by study arm in the rate of acquisition of CT or GC. However, our per-protocol
results suggest that consistent use of the diaphragm may reduce acquisition of GC.
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Introduction
The feminization of HIV/AIDS in recent years has under-
scored the urgent need for safe and effective women-initiated
HIV/STI prevention options. Sub-Saharan Africa is home to 68%
of HIV-infected people worldwide, with Southern Africa being the
epicenter of the pandemic [1]. Recent epidemiological studies
suggest a high incidence of both HIV and STIs among women in
Southern Africa coupled with low condom use. Despite intensive
condom counseling, many women in these settings are unable to
negotiate condom use with their male partners [2].
Concerted efforts are being made to develop new female
initiated methods of HIV/STI prevention but finding a safe and
effective product is challenging. Several trials of candidate
microbicides have had disappointing outcomes [3–7].
Observational studies suggest that women who use physical
barriers that cover the cervix have lower rates of infections with
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC), which
preferentially infect the cervix and upper genital tract [8–11].
Although it is no longer widely used, the vaginal diaphragm is a
female-initiated barrier method which has been available
worldwide as a contraceptive method for decades. The proposed
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3488mechanism of prevention of pregnancy and STIs is that the device,
which is worn internally, acts as a physical barrier of the cervix
and prevents sperm and infectious pathogens from ascending into
the upper genital tract [12].
We recently reported the primary results of a phase III multisite
evaluation of the diaphragm for HIV prevention: the Methods for
Improving Reproductive Health in Africa (MIRA) trial of the
Diaphragm and ReplensH lubricant gel showed that the interven-
tion offered no added protection against HIV when offered with a
comprehensive HIV prevention package, including male condoms,
safer sex counseling and treatment of sexually transmitted infections
in both arms [3]. The secondary objective of the MIRA trial,
reported here, was to determine the effectiveness of the diaphragm
and lubricant gel in preventing CT and GC cervical infections
among women at risk for sexually transmitted infections.
Methods
The MIRA trial was conducted in Durban and Johannesburg,
South Africa and Harare, Zimbabwe between 2003 and 2006.
The study protocol was reviewed and approved by all participating
institutions’ ethical review boards, including that of the University
of California, San Francisco (UCSF). After trial completion, UCSF
investigators, moved to RTI International. Ethics approval from
RTI International was treated as an exempt application to
continue data analysis and manuscript writing. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1.
Participants
Women were recruited from the general community, family
planning clinics and general health clinics. In Zimbabwe the study
was conducted at two clinics in the greater Harare area: Epworth
and Chitungwiza. In Durban, the study was also conducted at 2
clinics; in Umkomaas and Botha’s Hill. In Johannesburg, the clinic
was based at the Chris Hani Baragwanath Hospital in Soweto.
Eligibility criteria have been described in detail elsewhere [3].
Briefly, women had to have a healthy cervix and be: sexually
active; between 18 and 49 years old; HIV negative; CT and GC
negative at screening, (or willing to be treated if positive); and be
willing to follow all study protocol requirements. Women were
excluded from the study if they: were allergic to latex; had a
history of toxic shock syndrome; were pregnant and/or desired to
become pregnant; had previously undergone a total hysterectomy;
had clinical evidence of epithelial disruption or lesions; had
undergone pelvic surgery in the past 6 weeks; reported illicit drug
use; or were unable or unwilling to insert the diaphragm correctly
after 5 attempts. All women provided written informed consent at
screening and enrollment visits.
Intervention
Eligible consenting women were randomized into one of two
groups. In the intervention group, women received a clinician-
fitted diaphragm (All Flex Arching Spring diaphragm: Ortho-
McNeil Pharmaceutical, Raritan, NJ, USA), a supply of lubricant
gel (ReplensH, Lil Drug Store Products, Cedar Rapids, IA, USA)
and male condoms. Women randomized to the control group
received male condoms only. Participants in both groups received
a comprehensive HIV prevention package consisting of HIV/STI
pre- and post-test counseling, treatment of curable laboratory-
diagnosed STIs, and intensive risk reduction counseling.
Those in the intervention arm were counseled to insert the
diaphragm into the vagina at any convenient time before sexual
intercourse. Women were instructed to empty an applicator of gel
(2.5 g) into the dome of the diaphragm and to spread some gel onto
the rim before insertion. They were asked to apply a vaginal dose of
gel #1 h prior to intercourse for any additional sexual acts. Women
were asked to leave the diaphragm in situ for six hours after their last
act of sexual intercourse. At each visit, women were provided with a
three month supply of the gel based on their self-report of coital
frequency and could return to the clinic for more if desired. All
women were counseled to use condoms for every sexual act as the
effectiveness of the diaphragm for HIV/STI prevention was
unknown. Women were given a supply of condoms, as above,
and invited to come for a re-supply at any time. Women were also
informed that although the diaphragm is an effective contraceptive
when used with a spermicide, its efficacy for pregnancy prevention
when used without a spermicide was not known. Women were
counseled to use an effective contraceptive method and could
receive free hormonal contraception at the study clinics.
Randomization and Masking
Details of the randomized scheme are published elsewhere [3].
In brief, participants were randomized to assigned treatment
groups using a permuted block randomization scheme, with block
size stratified by study site. Consecutive participants were assigned
by sequentially drawing an opaque, sealed envelope. Given the
nature of the intervention, group assignment was not blinded to
the participant or the clinical team. Statistical analyses were based
on methods specified in an analytic plan completed prior to
unblinding of the randomized treatment assignments.
Procedures and outcomes
At the screening visit, consenting participants were offered HIV
pre-test counseling before HIV and STI testing. A behavioral
questionnaire on demographics and sexual behavior was admin-
istered by trained interviewers. HIV diagnostic testing was done
using two rapid tests on whole blood from either finger-prick or
venipuncture: Determine HIV-1/2 (Abbot Laboratories, Tokyo,
Japan) and Oraquick (Orasure Technologies, Bethlehem, PA,
USA). All women were counseled following their test. Those found
to be HIV infected were referred to appropriate referral clinics for
HIV care in their community.
For diagnosis of cervical STIs, a first catch urine sample was
collected for DNA PCR testing for GC and CT (Roche
Pharmaceuticals, Branchburg, NJ, USA). Trichomonas Vaginalis
(TV) was also diagnosed with a urine sample using DNA PCR
(Roche Pharmaceuticals, Branchburg., NJ, USA). Assays were
performed in two laboratories, one each in Zimbabwe and South
Africa. Each of the 2 laboratories participated in quality control
programs locally and internationally, and was monitored annually
by a study monitor who reviewed all non-negative laboratory test
results. All assays were run with appropriate positive and negative
controls and the laboratories participated in external proficiency
testing for all available analytes. Systematic review of all positive
results and tracing back to source documents detected (and
rectified) clerical errors. PCR and ELISA assays were also
reviewed for clustering of results that might suggest contamination
and sample spill-over. Internal controls were used to validate
negative PCR results. Urine specimens were stored in 220uC
freezers for a maximum of 14 days before testing. Urine was the
specimen of choice as a result of the use of cervical products in this
trial that may have affected the quality of either cervical or vaginal
samples. The GC PCR assay has been validated for use on female
urine by many clinical diagnostic laboratories in the US and
Western Europe. The use of a stringent definition of a positive
result was implemented in this study in order to maintain high
specificity [13]. Women with positive STI tests results were treated
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and a STAT dose of 500 mg Ciprofloxacin for GC. In the third
year of the trial, the latter was amended to ceftriaxone 125 mg IM
for the South African sites because of emerging quinolone
resistance in local GC isolates. Of all the baseline cases, 11
women with positive CT tests were untreated or treated
inadequately, that is not according to protocol (10 cases in
Harare, 1 case in Durban). Similarly, 3 women with baseline
positive GC tests were untreated or treated inadequately (2 cases
in Harare, 1 case in Durban).
At the enrollment visit, after participants provided written
informed consent, a pelvic exam was performed by a study
clinician. In addition, a blood sample was collected for syphilis
(rapid plasma regain (RPR) and Treponema pallidum heamagglutinin
(TPHA), Randox Laboratories, Crumlin, UK) and herpes simplex
virus 2 testing (HSV2: ELISA, FOCUS Diagnostics, Cypress,CA,
USA) and urine for pregnancy testing (results not presented here).
All women received education and demonstration of diaphragm
insertion and removal using a pelvic model, and had the
opportunity to practice using this model. Women in both arms
had to demonstrate the ability to insert and remove the diaphragm
to be eligible for the study. All enrolled women completed an
Audio Computer Assisted Self-interview (ACASI) baseline ques-
tionnaire on demographics, sexual behavior and product use.
After enrollment each woman, regardless of randomization
arm, was scheduled to return to the clinic after two weeks to
address any difficulties with product use and to provide
appropriate counseling about product use and risk reduction. At
each quarterly follow-up visit, we conducted HIV and STI
counseling and testing, treatment of curable STIs (as applicable),
product adherence and risk reduction counseling and pregnancy
testing. If self-report of adverse events warranted it, and at all
closing visits, women received a pelvic examination. Product use
was assessed by ACASI at every quarterly visit.
Statistical considerations
The initial study sample of 4500 women was selected to provide
90% power to detect an intervention-related decrease in HIV
incidence of at least 33%, significant at the 5% level. Other
outcomes were not considered in the supporting calculations. Lower
than expected overall incidence of HIVin the first months of follow-
up led to the decision to increase the total sample size, leading to the
final total sample of 5045 women. The study data was reviewed
twice in November 2005 and May 2006 by an independent Data
Safety Monitoring Board (DSMB), with monitoring criteria focused
on the primary HIV outcome. Further details on statistical issues in
study design and monitoring have been reported previously [3].
Incident infection was defined as time from enrollment to first
CT or GC infection using the discrete time scale determined by
the quarterly visit schedule. The primary analysis was conducted
using an Intent-to-Treat (ITT) approach, which included all
randomized participants. The ITT analysis was based on a Cox
proportional hazards model for discrete time outcomes including a
binary indicator of group assignment as the only predictor
variable, and allowing for study site-specific baseline hazards.
The results of the primary analysis were summarized by the
estimated relative hazard comparing CT or GC incidence in the
intervention group to that in the control group, with the associated
95% confidence interval (CI). Modified ITT analyses were
conducted, removing from each sample the untreated or
inadequately treated CT or GC cases. We used generalized
estimating equation (GEE) logistic regression for longitudinal
outcome measures [14] to examine site differences in levels of
condom use at last sex, among women in the intervention arm.
Assessment of the safety of the intervention is not reported here, as
it has been previously published [3], with the proportions of
participants reporting adverse events and serious adverse events,
including those related to the reproductive tract, being similar
across sites and between groups.
For the per-protocol analysis, two different measures of
‘‘diaphragm use’’ were considered: use at last sex and ‘‘always
use’’ since last quarterly visit (both measured by ACASI). Because
diaphragm and gel use were highly correlated (van der Straten et
al., unpublished manuscript), for simplicity, we limited our
examination of product use to that of the diaphragm. The per-
protocol analysis repeated the between-group comparisons of
outcomes excluding data from visits meeting the following
conditions: visits for women in the intervention group where
diaphragm use was not reported and visits for women in the
control group where diaphragm use was reported.
Results
A total of 10,941 women were screened. Prevalence of HIV and
cervical STIs in the screening population was higher in Durban
compared to Johannesburg and Harare. The HIV prevalence was
39% in Durban, 31% in Harare and 21% in Johannesburg. The
prevalence of CT was 8.5%, 6.9% and 2.0% at Durban,
Johannesburg and Harare, while prevalence of GC was 2.7% in
Durban, 1.1% and 0.9% in Johannesburg and Harare, respec-
tively (data not shown).
As shown in Figure 1, of the total screened 5,045 women were
randomized. The final analytic sample included 4,968 participants
who had at least one follow-up urine sample for CT/ GC analysis,
including 2468, 1492 and 1008 women from Harare, Durban and
Johannesburg, respectively. Rates of discontinuation (including
both withdrawals and loss to follow up) were similar between both
arms. The median follow-up period was 21 months and 93% of
the women completed a scheduled study closing visit.
The baseline characteristics and reported sexual behavior were
similar in both study groups: 31.2% reported always using condoms
in the previous 3 months and two-thirds (65.4%) reported a coital
frequency of 3 times or less per week; 36.2% reported using oral
contraceptive pills for contraception, and 24.7% injectables, while
20.3% used a barrier method, predominantly male condoms
(Table 1). Similar proportions of women (15.8%) in both groups
tested positive for STI at screening (including CT, GC, syphilis and
TV). In the enrolled population, the prevalence at screening for CT
and GC, was 4.6% and 0.8%, respectively.
There were 471 first incident CT infections among 4968
participants during study follow-up, 247 among women assigned
to the intervention arm and 224 among women assigned to the
control arm with an overall incidence of 6.2/100 woman-years (wy)
(Table 2). ITT analysis revealed no difference in the incidence of
CT between treatment assignment groups (RH 1.11, 95% CI 0.93–
1.33, p=0.25). There was a significantly higher rate of CT infection
in the intervention arm compared to control arm at the
Zimbabwean site. The same was not observed at the South African
sites. A modified ITT analysis excluding 11 participants with
untreated or inadequately treated CT at baseline resulted in similar
findings (data not shown). Figure 2 shows the Kaplan–Meier group-
specific estimate of cumulative probability of CT acquisition.
There were 192 first incident GC infections among 4968
participants during study follow-up, 95 infections among women
assigned to the intervention arm and 97 among women assigned to
the control arm with an overall incidence of 2.4/100wy (Table 3).
ITT analysis also revealed no difference between the intervention
and control groups with regard to the incidence of first GC
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analysis excluding three participants with untreated or inade-
quately treated GC at baseline resulted in similar findings (data not
shown). In contrast to CT, there were no significant differences
observed at the site level between intervention and control arms.
Figure 3 displays the Kaplan Meier curve showing the proportion
of women infected with GC over time since enrollment.
We also conducted a per-protocol (PP) analysis to examine the
possible contribution of diaphragm adherence to our results
(Tables 4 and 5). In the PP analysis we observed that participants
in the intervention arm had a non-significant reduction in the risk
of CT acquisition when adherence was defined as diaphragm use
at last sex (RH 0.90, 95% CI 0.72–1.13, p=0.35); we found
similar results when it was defined as ‘‘always use’’ of the
diaphragm since the last quarterly visit (RH 0.84, 95% CI 0.67–
1.06, p=0.15). Of note, in both per protocol analyses, the relative
hazard for CT infection at the Zimbabwean site was no longer
significantly elevated. The risk of GC infection in PP analyses was
also reduced, albeit non-significantly, when considering dia-
phragm use at last sex (RH 0.74, 95% CI 0.52–1.04, p=0.09).
When adherence was defined as ‘‘always use’’ of the diaphragm
since the last quarterly visit, there was a significant reduction in the
incidence of GC among women assigned to the intervention arm
(RH 0.61, 95% CI 0.41–0.91, p=0.02).
Overall, condom use at last sex in the intervention arm was
reported 54% of the time, 51% in Harare, 55% in Durban and
62% Johannesburg. Site differences were statistically significant
(data not shown).
Figure 1. CONSORT Flow Diagram (CT/GC Trial Profile).
doi:10.1371/journal.pone.0003488.g001
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Category Subcategory
Total
(n=5039) Total (%)
Intervention arm
(%, n=2521)
Control arm
(%, n=2518)
Age 24 years old or younger 1933 38.4 39.6 37.2
25 to 34 years old 1972 39.1 38.5 39.8
35 years old or older 1133 22.5 22.0 23.0
At least high school education - 2214 44.0 45.0 43.0
Living Together - 3402 67.5 67.4 67.6
Coital frequency (per week) 3 times or less 3296 65.4 65.0 65.8
.3 times 1743 34.6 35.0 34.2
Regular partner circumcised Yes 1087 21.6 22.4 20.8
No 2945 58.6 57.8 59.4
Don’t know 995 19.8 19.8 19.8
Tested positive for STI(s)
1 - 794 15.8 15.4 16.2
Tested positive for CT - 231 4.6 4.4 4.8
Tested positive for GC - 39 0.77 0.91 0.64
Tested positive for TV or Syphilis - 579 11.5 11.1 11.9
Tested positive for HSV-2 (enrollment) - 2947 58.5 57.1 59.9
High behavior risk: at least one indicator vs. none
2 - 1440 28.7 27.9 29.4
High partner risk: at least one indicator vs. none
3 - 3447 68.6 68.7 68.5
Frequency of condom use in past 3 months (enrollment) Never 1499 29.8 30.1 29.6
Sometimes 1959 39.0 39.8 38.1
Always 1570 31.2 30.2 32.3
Current contraceptive use (screening) Long term
4 304 6.0 6.0 6.1
Injectable hormones 1242 24.7 24.1 25.2
Pill
5 1825 36.2 36.3 36.1
Barrier
6 1024 20.3 21.1 19.5
Other/none 644 12.8 12.5 13.1
1At least one positive test for CT, GC, TV or Syphilis at screening or enrollment.
2Indicators include: Any exchange of sex for money/food/drugs/shelter, 2 or more sexual partners within last 3 months, ever had vaginal sex under influence of drugs/
alcohol in last 3 months, ever used needle for injectable drug use, ever had anal sex.
3Indicators include: Having any sexual partners test positive for HIV, Suspect or know that regular partner had other sex partners in the last 3 months, ever had vaginal
sex when partner was under influence of drugs/alcohol in last 3 months, regular partner was away from home for 1 or more months.
4Long term methods include tubal ligation, vasectomy, IUD, implants such as Jadelle & Norplant.
5Pill methods include combined oral contraceptive and progesterone only pills.
6Barrier methods include male or female condoms.
doi:10.1371/journal.pone.0003488.t001
Table 2. Summary of CT, overall and by site (n=4968).
Trial Site Study Arm
Total no. of
participants
No. of
events
Cumulative
proportion of
infections (%)*
Relative Hazard
(95% CI) Intervention
vs. Control arm p-value
All Overall 4968 471 9.48 - -
Intervention 2487 247 9.93 - -
Control 2481 224 9.03 1.11 (0.93, 1.33) 0.25
Harare Intervention 1236 85 6.88 - -
Control 1232 53 4.30 1.63 (1.15, 2.29) 0.01
Durban Intervention 748 98 13.10 - -
Control 744 102 13.71 0.96 (0.73, 1.27) 0.79
Johannesburg Intervention 503 64 12.72 - -
Control 505 69 13.66 0.93 (0.66, 1.31) 0.68
*Over entire follow-up period.
doi:10.1371/journal.pone.0003488.t002
Prevention of Cervical STIs
PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3488Discussion
This is the first randomized controlled trial to evaluate the effect
of providing a diaphragm and lubricant gel on acquisition of
cervical STIs. By ITT analysis, we found no added benefit of
providing the diaphragm and lubricant gel, over and above that of
condoms, on the rate of CT or GC acquisition. However, by per-
protocol analysis, for those women reporting consistent (always in
the past three months) diaphragm use, we observed a reduced risk
of cervical gonococal infection. A similar trend, although not
significant, was noted for chlamydial infection. Of note, in MIRA,
condom use was lower in the intervention arm compared to the
control arm [3]. This observation, combined with our finding that
reported consistent diaphragm use may confer some protection
Figure 2. Cumulative probability of CT infection (Kaplan-Meier estimates) by group.
doi:10.1371/journal.pone.0003488.g002
Table 3. Summary of GC, overall and by site (n=4968).
Trial Site Study Arm
Total no. of
participants
No. of
events
Cumulative
proportion of
infections (%)*
Relative Hazard
(95% CI) Intervention
vs. Control arm p-value
All Overall 4968 192 3.86 - -
Intervention 2487 95 3.82 - -
Control 2481 97 3.91 0.98 (0.74, 1.30) 0.90
Harare Intervention 1236 29 2.35 - -
Control 1232 27 2.19 1.07 (0.64, 1.81) 0.79
Durban Intervention 748 43 5.75 - -
Control 744 42 5.65 1.03 (0.68, 1.58) 0.88
Johannesburg Intervention 503 23 4.57 - -
Control 505 28 5.54 0.83 (0.48, 1.43) 0.50
*Over entire follow-up period.
doi:10.1371/journal.pone.0003488.t003
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need to adjust for possible confounding factors such as condom use
that may be associated with both self reported use of diaphragms
and with infection outcomes, and account for the possibility of
error in self-reports of diaphragm and condom use.
A recently published observational acceptability study of the
vaginal diaphragm among female sex workers and women
attending sexual and reproductive health services in Kenya
reported a lower incidence of gonococcal infection among women
who always used the diaphragm (28.6/100wy of observation)
compared to women who inconsistently used the diaphragm (48/
100wy) (rate ratio 0.60, 95% CI 0.17–1.87, p=0.34) [15].
Another RCT of the diaphragm combined with a microbicide
to prevent reinfection of cervical STIs is underway in a different
population [16]. If high adherence is achieved in that trial and it is
demonstrated that diaphragms can prevent cervical STIs or at
least GC, then there may be a public health benefit of adding the
diaphragm to the prevention method mix to address the risk of
STI among at-risk women.
Although exploration of site differences was beyond the scope of
our analytic plan and this paper, our analyses offered no
immediate explanations for the increased risk of first CT
acquisition at the Harare site, observed by ITT analysis. Removal
of untreated or inadequately treated baseline CT cases (most of
which were in Harare) did not change the finding. Condom use at
last sex in the intervention arm was lowest in Harare, but only by
4% compared to Durban, a difference which is unlikely to explain
the elevated risk for CT in Harare. Furthermore there was no
elevated risk for GC in Harare. Laboratory- or data-related errors
were ruled out given excellent reliability performances of the
laboratory and no abnormalities identified during regular
laboratory monitoring visits at the site. Furthermore, laboratories
were blinded to the participant study arms, so all specimens were
treated the same. Finally no elevation in risk of GC was noted in
Harare, and as GC and CT tests were run together, a laboratory
test problem with CT is unlikely to explain this finding.
Importantly, as the elevated risk for CT in the intervention arm
in Harare was attenuated in the per protocol analyses, it is unlikely
to be due to a harmful effect of using the diaphragm.
Prevention technologies currently undergoing clinical trials may
or may not prevent STI infections in addition to HIV. Indeed,
second generation microbicides containing ARV medications, pre-
exposure prophylaxis, or vaccines are specific to HIV only and do
not address the need for STI prevention. Although six randomized
controlled trials to measure the effect of STI treatment on HIV
transmission have been conducted, only the first study in Mwanza,
Tanzania found nearly 40% reduction in HIV when STIs were
treated through syndromic management [17], whilst the others
showed no effect [18–22]. In addition two recent intervention
trials to reduce HSV2 acquisition for HIV prevention also had
disappointing outcomes [23,24]. Nonetheless, STI prevention
remains critical to prevent the significant morbidity due to non-
HIV STIs, and also because these infections increase the risk of
HIV acquisition.
Figure 3. Cumulative probability of GC infection (Kaplan-Meier estimates) by group.
doi:10.1371/journal.pone.0003488.g003
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Measure of
diaphragm use Trial Site Study Arm
Total no. of
participants
No. of
events
Cumulative
proportion of
infections (%)*
Relative Hazard
(95% CI) Intervention
vs. Control arm p-value
Used at last sex All Overall 4552 307 6.74 - -
Intervention 2164 130 6.01 - -
Control 2388 177 7.41 0.90 (0.72, 1.13) 0.35
Harare Intervention 1148 48 4.18 - -
Control 1195 43 3.60 1.24 (0.82, 1.88) 0.30
Durban Intervention 621 51 8.21 - -
Control 722 81 11.22 0.81 (0.57, 1.15) 0.24
Johannesburg Intervention 395 31 7.85 - -
Control 471 53 11.25 0.73 (0.47, 1.14) 0.17
Always used in
past three months
All Overall 4401 311 7.07 - -
Intervention 1959 110 5.62 - -
Control 2442 201 8.23 0.84 (0.67, 1.06) 0.15
Harare Intervention 1075 44 4.09 - -
Control 1228 49 3.99 1.15 (0.77, 1.73) 0.49
Durban Intervention 560 43 7.68 - -
Control 737 94 12.75 0.73 (0.51, 1.05) 0.09
Johannesburg Intervention 324 23 7.10 - -
Control 477 58 12.16 0.71 (0.44, 1.15) 0.16
*Over entire follow-up period.
doi:10.1371/journal.pone.0003488.t004
Table 5. Summary of GC per-protocol analyses (non-adherent participant visits were excluded).
Measure of
diaphragm use Trial Site Study Arm
Total no. of
participants
No. of
events
Cumulative
proportion of
infections (%)*
Relative Hazard
(95% CI) Intervention
vs. Control arm p-value
Used at last sex All Overall 4607 138 3.00 - -
Intervention 2197 52 2.37 - -
Control 2410 86 3.57 0.74 (0.52, 1.04) 0.09
Harare Intervention 1161 18 1.55 - -
Control 1198 26 2.17 0.75 (0.41, 1.38) 0.36
Durban Intervention 631 22 3.49 - -
Control 732 38 5.19 0.76 (0.45, 1.29) 0.31
Johannesburg Intervention 405 12 2.96 - -
Control 480 22 4.58 0.68 (0.34, 1.38) 0.29
Always used in past
three months
All Overall 4428 124 2.80 - -
Intervention 1976 35 1.77 - -
Control 2452 89 3.63 0.61 (0.41, 0.91) 0.02
Harare Intervention 1082 15 1.39 - -
Control 1229 23 1.87 0.83 (0.43, 1.59) 0.57
Durban Intervention 568 12 2.11 - -
Control 739 41 5.55 0.48 (0.25, 0.91) 0.03
Johannesburg Intervention 326 8 2.45 - -
Control 484 25 5.17 0.60 (0.27, 1.33) 0.21
*Over entire follow-up period.
doi:10.1371/journal.pone.0003488.t005
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technologies do not specifically target any STIs, we believe that a
combination of prevention options may be necessary for
addressing both the current HIV and STI epidemics. If future
RCTs can demonstrate that the diaphragm reduces cervical
infections, using a diaphragm as a physical barrier together with
another HIV-specific intervention such a vaccine, second-
generation microbicide, or pre-exposure prophylaxis, may have
a significant public health benefit.
We could not confirm prior observational findings indicating a
protective effect of the diaphragm on acquisition of cervical STIs
[8,10,15]. However, our results suggest that consistent use of the
diaphragm with lubricant gel may partially protect against some
cervical infections. The biological plausibility of diaphragm use to
prevent cervical STI remains, provided that the barrier methods is
used correctly and consistently [12]. At a minimum, this
hypothesis warrants future study.
Supporting Information
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